# Amberstone Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amberstone-biosciences

- Industry: Biotechnology
- Headquarters: Laguna Hills, US
- Website: www.amberstonebio.com
- Total disclosed funding: $6M
- Latest round: Series A (Nov 9, 2021)
- Investors on record: 5

## About

Based in California, US, and founded in 2018 by CEO George Wu, Amberstone Biosciences, Inc. discovers therapeutic antibodies to treat solid tumor cancers and other diseases. In January 2022, Amberstone Biosciences, Inc. raised USD 12 million in a Series A funding co-led by Co-Win Ventures, Sinovation Ventures, and Viva BioInnovator, with participation from Changrong Capital and Lifespan Investments.  

Amberstone Biosciences, Inc. develops intramural antibody programs and advances its biopharmaceutical partners’ immunotherapy pipelines. The company uses AmberFlow, a single cell platform that enables decidedly efficient isolation of antibody-drug candidates. In addition, Amberstone Biosciences, Inc. is developing immunotherapeutic pipeline assets.

Amberstone Biosciences, Inc. plans to use its proceeds from a Series A funding to advance its tumor microenvironment-activated therapeutic programs including immune cytokines and bispecific antibodies to the investigational new drug application (IND) enabling stage.

## Funding rounds

- Series A, Nov 9, 2021, $6M — Sinovation Ventures, Co-Win Ventures, Changrong Capital, Viva BioInnovator, Lifespan Investments

## Investors

- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Series A
- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A
- Changrong Capital — Series A
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series A
- Lifespan Investments — Series A